Business Context and Reporting Period
This Form 8-K was filed by Eyenovia, Inc. (not Hyperion Defi, Inc.) on August 24, 2023. The registrant is a Delaware corporation trading on the Nasdaq Capital Market under the symbol EYEN. The filing reports the entry into a material definitive agreement for a registered direct offering and an amendment to prior warrants.
Key Financial Metrics and Transaction Details
The filing details a capital raise rather than periodic financial performance metrics (revenue, profit, or cash flow are not reported in this document).
- Offering Structure: Sale of 4,198,633 shares of Common Stock, 2,252,979 Pre-Funded Warrants, and 4,838,709 Warrants.
- Offering Prices: $1.86 per Share/Warrant unit; $1.85 per Pre-Funded Warrant/Warrant unit.
- Warrant Terms:
- New Warrants: Exercisable after 6 months for 5 years at $2.23/share.
- Pre-Funded Warrants: Immediately exercisable at $0.01/share.
- Net Proceeds: Approximately $10.9 million after deducting fees and expenses.
- Transaction Costs: 6.5% cash fee to placement agents (William Blair & Company, L.L.C. and Brookline Capital Markets) plus up to $150,000 in expense reimbursement.
Material Changes and Prior Warrant Amendment
In connection with the offering, the Company amended previously issued warrants (covering 4,870,130 shares) with the following changes:
- Exercise Price Reduction: Lowered from $3.54 to $2.23 per share.
- Term Extension: Extended until March 1, 2029.
- Exercise Restriction: Prohibited exercise for six months following the amendment's effective date.
- Ownership Limitation: Added a stockholder approval requirement for modifying the beneficial ownership limitation.
Outlook, Use of Proceeds, and Risks
Use of Proceeds: The Company intends to use the net proceeds for:
- Commercialization of a post-ophthalmic surgery product with a PDUFA date in March 2024 (targeting a $1.3 billion market).
- Manufacturing automation for the Optejet® device.
- Working capital and general corporate purposes.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Actual outcomes may differ due to regulatory approval risks, market conditions, and the uncertainty of the offering closing (expected on or about August 29, 2023).
Investor Verification Checklist
- Verify the final closing date of the offering (expected August 29, 2023) and actual net proceeds received.
- Confirm the regulatory status and PDUFA timeline for the post-ophthalmic surgery product scheduled for March 2024.
- Review the full text of the Warrant Amendment Agreement (Exhibit 10.2) to understand the specific conditions of the prior warrant modification.
- Monitor the Company's cash burn rate relative to the $10.9 million raised to assess runway for commercialization activities.